Department of Geosciences, Johannes Gutenberg University Mainz, Mainz, Germany.
PLoS One. 2013 Aug 5;8(8):e70617. doi: 10.1371/journal.pone.0070617. Print 2013.
To investigate potential differences in stone composition with regard to the type of Primary Hyperoxaluria (PH), and in relation to the patient's medical therapy (treatment naïve patients versus those on preventive medication) we examined twelve kidney stones from ten PH I and six stones from four PH III patients. Unfortunately, no PH II stones were available for analysis. The study on this set of stones indicates a more diverse composition of PH stones than previously reported and a potential dynamic response of morphology and composition of calculi to treatment with crystallization inhibitors (citrate, magnesium) in PH I. Stones formed by PH I patients under treatment are more compact and consist predominantly of calcium-oxalate monohydrate (COM, whewellite), while calcium-oxalate dihydrate (COD, weddellite) is only rarely present. In contrast, the single stone available from a treatment naïve PH I patient as well as stones from PH III patients prior to and under treatment with alkali citrate contained a wide size range of aggregated COD crystals. No significant effects of the treatment were noted in PH III stones. In disagreement with findings from previous studies, stones from patients with primary hyperoxaluria did not exclusively consist of COM. Progressive replacement of COD by small COM crystals could be caused by prolonged stone growth and residence times in the urinary tract, eventually resulting in complete replacement of calcium-oxalate dihydrate by the monohydrate form. The noted difference to the naïve PH I stone may reflect a reduced growth rate in response to treatment. This pilot study highlights the importance of detailed stone diagnostics and could be of therapeutic relevance in calcium-oxalates urolithiasis, provided that the effects of treatment can be reproduced in subsequent larger studies.
为了研究原发性高草酸尿症(PH)类型与患者医疗治疗之间结石成分的潜在差异(治疗初治患者与预防药物治疗患者),我们检查了 10 例 PH I 型和 6 例 PH III 型患者的 12 颗肾结石和 6 颗肾结石。遗憾的是,没有 PH II 结石可供分析。对这组结石的研究表明,PH 结石的成分比以前报道的更为多样化,并且在 PH I 中使用结晶抑制剂(柠檬酸盐、镁)治疗时,结石形态和成分可能存在动态变化。接受治疗的 PH I 型患者形成的结石更致密,主要由一水合草酸钙(COM,whewellite)组成,而二水合草酸钙(COD,weddellite)很少存在。相比之下,单一的治疗初治 PH I 型患者结石,以及在碱柠檬酸治疗之前和治疗期间 PH III 型患者的结石,都包含范围广泛的聚集 COD 晶体。PH III 型结石未观察到明显的治疗效果。与以前的研究结果不一致的是,原发性高草酸尿症患者的结石并不完全由 COM 组成。COD 晶体的小 COM 晶体的渐进性替代可能是由于结石在泌尿道中生长和停留时间延长所致,最终导致二水合草酸钙完全被一水合形式取代。与初治 PH I 型结石的显著差异可能反映了对治疗的生长速度降低。这项初步研究强调了详细结石诊断的重要性,如果在后续更大规模的研究中能够重现治疗效果,这可能对草酸钙尿石症具有治疗意义。